Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches
JCO Oncology Advances · 2025-04 · (2)
DOI: 10.1200/oa-24-00077 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCO Oncology Advances, 2025-04. Verfasst von Kelly Pum und 5 weiteren Autor:innen. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 68 Literaturangaben.
Abstract (Originalsprache)
There have been significant advances in colorectal cancer (CRC) immunotherapy over the past decade, with incorporation into both the metastatic and adjuvant/neoadjuvant treatment spaces. However, there remains a large unmet need in the CRC population, with a minority of cancers currently addressable with existing immunotherapeutic solutions. This review summarizes both our current approach and the novel therapeutics, which may soon be a part of standard practice. Current treatments focus on targeting inhibiting PD-1 and cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) pathways with antibodies, such as pembrolizumab, nivolumab, and ipilimumab. Meanwhile, there are numerous novel immunotherapeutic approaches being investigated. Recent studies have shown that Fc-enhanced PD-1/CTLA-4 antibodies can have an impact in microsatellite stable CRC. Other work has evaluated new combinatorial pathways with classic PD-1 blockade to expand response, such as LAG-3, TIGIT, and NKG2A. These treatments have been used in trials for use in metastatic CRC and in possible novel adjuvant/neoadjuvant therapies. Additional immune checkpoint inhibitor options may be incorporated into CRC trials in the near future as regimens targeting TIM-3, OX40, CD137, and VISTA, among others, have been recently investigated in advanced solid tumor trials. These approaches suggest a bright future for CRC immunotherapy with an expansion of effective immunotherapeutic options available for patients with CRC, leading to improved outcomes and quality of life.
Zitieren
APA
Pum, K., LaRocca, C. J., Goffredo, P., Subramanian, S., Lou, E., & Prakash, A. (2025). Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches. JCO Oncology Advances. https://doi.org/10.1200/oa-24-00077
Vancouver
Pum K, LaRocca CJ, Goffredo P, Subramanian S, Lou E, Prakash A. Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches. JCO Oncology Advances. 2025. doi:10.1200/oa-24-00077
BibTeX
@article{Pum2025,
author = {Pum, Kelly and LaRocca, Christopher J. and Goffredo, Paolo and Subramanian, Subbaya and Lou, Emil and Prakash, Ajay},
title = {Immune Checkpoint Blockade Therapies for Colorectal Cancer: Current Strategies and Emerging Approaches},
journal = {JCO Oncology Advances},
year = {2025},
number = {2},
doi = {10.1200/oa-24-00077}
}
EUVIMED